The study found a significant increase in the number of CD8+T cells in patients, with clinical benefit; the probability of progression-free survival at 6 months and 12 months in patients with refractory HCC was 57.1% and 33.1%, respectively, and the median time to tumor progression was 7.4 months. This evidence concerns the gene CD8A and neoplasm.